Private equity firm makes ‘significant’ investment in Charnwood Molecular

Charnwood Molecular's new site

Life sciences firm Charnwood Molecular has received investment from a private equity fund which will see it embark on a rapid expansion plan.

Synova has made a “significant” investment into the Charnwood, which will bring additional senor leadership team members into the company and see it become the sole occupier of a 3-storey laboratory at the Charnwood Campus in Loughbourough.

CEO of Charnwood Molecular, Steve Allin, said: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines.”

John Handley, managing director of Charnwood Molecular, added: “Our expansion plans for the business are now coming to fruition. From hiring significant numbers of new scientists at both of our existing research sites, through to a doubling of our business development team and now adding much larger bespoke facilities, we are looking to the future to make Charnwood Molecular a very major player in the discovery CRO marketplace.”

Gosia Khrais, commercial and marketing director at Charnwood Campus said: “It is a great pleasure to welcome Charnwood Molecular as a new occupier here. This fantastic CRO with ambitious growth plans will cement life sciences as a priority sector in the region, create jobs and help us grow our local economy. It is really great news for Loughborough.”